CORDIS
EU research results

CORDIS

English EN
Artificial vascularised scaffolds for 3D-tissue-regeneration

Artificial vascularised scaffolds for 3D-tissue-regeneration

Objective

The use of bioartificial tissue for regenerative medicine offers great therapeutic potential, but also has to meet high demands with respect to the interaction of the bioartificial devices and natural tissues. Key issues for the successful use of bioartifical tissues as natural tissue replacements are their long term functional stability and biocompatible integration. Up to now, various approaches for the generation of bioartificial tissues have not succeeded due to insufficient nutrition and oxygen supply. Therefore, current tissue engineered products have only been realised for non vascularised tissues such as cartilage.
ArtiVasc 3D will break new ground and overcome these challenges by providing a micro- and nano-scale based manufacturing and functionalisation technology for the generation of fully vascularised bioartificial tissue that enables entire nutrition and metabolism. The bioartificial vascularised skin engineered in ArtiVasc 3D will, for the first time, allow tissue replacement with optimum properties.
ArtiVasc 3D will research and develop an innovative combination of hi-tech engineering such as micro-scale printing, nano-scale multiphoton polymerisation and electro-spinning with biological research on biochemical surface modification and complex cell culture. In a multidisciplinary approach, experts in biomaterial development, cell-matrix interaction, angiogenesis, tissue engineering, simulation, design and fabrication methods work together to generate bioartificial vascularised skin in a fully automated and standardised manufacturing approach.
This bioartificial vascularised skin will be of great value in a vast array of clinical treatments, e.g. as a transplant in trauma treatment. In addition, this new bioartificial vascularised skin will be used as an innovative in vitro skin equivalent for pharmaceutical, cosmetics or chemical substance testing, which represents a promising method to reduce expensive, ethically disputed animal testing.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Address

Hansastrasse 27c
80686 Munchen

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 207 375

Administrative Contact

Walter Krause (Mr.)

Participants (16)

Sort alphabetically

Sort by EU Contribution

Expand all

VIMECON GMBH

Germany

EU Contribution

€ 148 307

UNITECHNOLOGIES SA

Switzerland

EU Contribution

€ 528 562

AO-FORSCHUNGSINSTITUT DAVOS

Switzerland

EU Contribution

€ 90 054

UNIVERSITY OF EAST ANGLIA

United Kingdom

EU Contribution

€ 461 029

ALBERT-LUDWIGS-UNIVERSITAET FREIBURG

Germany

EU Contribution

€ 309 779

VEREIN ZUR FORDERUNG VON INNOVATIONEN DURCH FORSCHUNG ENTWICKLUNG UNDTECHNOLOGIETRANSFER EV

Germany

EU Contribution

€ 499 316

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 426 607

KMS Automation GmbH

Germany

EU Contribution

€ 374 999

AALTO KORKEAKOULUSAATIO SR

Finland

EU Contribution

€ 444 729,80

LOUGHBOROUGH UNIVERSITY

United Kingdom

EU Contribution

€ 328 876,80

UNIVERSITA DEGLI STUDI DI SALERNO

Italy

EU Contribution

€ 374 998,80

Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH

Germany

EU Contribution

€ 444 317

UNIVERSITAET STUTTGART

Germany

EU Contribution

€ 419 739,60

ARTTIC

France

EU Contribution

€ 377 632

BEIERSDORF AG

Germany

EU Contribution

€ 363 678

GLOBAL CLINICAL TRIALS MANAGEMENT AG

Switzerland

Project information

Grant agreement ID: 263416

Status

Closed project

  • Start date

    1 November 2011

  • End date

    31 October 2015

Funded under:

FP7-NMP

  • Overall budget:

    € 10 467 338,60

  • EU contribution

    € 7 800 000

Coordinated by:

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany